Imunon’s (IMNN) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Imunon (NASDAQ:IMNN) in a research report released on Wednesday morning,Benzinga reports. The brokerage currently has a $29.00 target price on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Imunon in a report on Thursday, December 19th.

Imunon Price Performance

Shares of NASDAQ IMNN opened at $0.92 on Wednesday. The stock’s fifty day moving average price is $0.89 and its two-hundred day moving average price is $0.96. Imunon has a one year low of $0.53 and a one year high of $3.65. The firm has a market cap of $13.33 million, a price-to-earnings ratio of -0.49 and a beta of 2.03.

Institutional Trading of Imunon

An institutional investor recently raised its position in Imunon stock. Geode Capital Management LLC lifted its stake in shares of Imunon, Inc. (NASDAQ:IMNN) by 10.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 139,505 shares of the company’s stock after purchasing an additional 13,570 shares during the quarter. Geode Capital Management LLC owned 0.96% of Imunon worth $133,000 as of its most recent SEC filing. Institutional investors and hedge funds own 4.47% of the company’s stock.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.